Drug Search Results
More Filters [+]

Daprodustat

Alternative Names: daprodustat, gsk1278863
Latest Update: 2024-05-24
Latest Update Note: Clinical Trial Update

Product Description

Daprodustat (Jesduvroq), a HIF-PHI, belongs to a novel class of oral medicines for the treatment of anaemia of CKD in adult patients on dialysis. Inhibition of oxygen-sensing prolyl hydroxylase enzymes stabilises hypoxia-inducible factors, which can lead to transcription of erythropoietin and other genes involved in the correction of anaemia, similar to the physiological effects that occur in the human body at high altitude (Sourced from: https://www.gsk.com/en-gb/media/press-releases/jesduvroq-daprodustat-approved-by-us-fda-for-anaemia-of-chronic-kidney-disease-in-adults-on-dialysis/)

Mechanisms of Action: HIF Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Japan | United States

Approved Indications: None

Known Adverse Events: None

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Daprodustat

Countries in Clinic: Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Colombia, Czech Republic, Denmark, Estonia, France, Germany, Greece, Hong Kong, Hungary, India, Israel, Italy, Japan, Korea, Malaysia, Mexico, Netherlands, New Zealand, Philippines, Poland, Portugal, Romania, Russia, Singapore, South Africa, South Korea, Spain, Sweden, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States, Unknown Location, Vietnam

Active Clinical Trial Count: 6

Highest Development Phases

Phase 3: Anemia|Kidney Diseases|Kidney Failure, Chronic

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ASCEND-P

P3

Recruiting

Anemia

2030-07-05

39%

jRCT2041220113

P3

Not yet recruiting

Anemia

2028-05-17

Anemia Studies in CKD

P2

Completed

Anemia

2022-07-05

NCT04640311

P1

Completed

Healthy Volunteers

2021-05-18

Recent News Events